LFG
DSGN icon

Larson Financial Group’s Design Therapeutics DSGN Stock Holding History

Larson Financial Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.93K Buy
181
+178
+5,933% +$1.8K ﹤0.01% 2966
2025
Q4 		$28 Hold
3
– – ﹤0.01% 3405
2025
Q3 		$23 Buy
+3
New +$15 ﹤0.01% 3390

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Larson Financial Group's DSGN Position: Q1 2026 in Review

Larson Financial Group increased its Design Therapeutics (DSGN) stake by 5,933% in Q1 2026, buying an estimated $1.8K and bringing the position to 181 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #2966.

Larson Financial Group first reported a position in DSGN in Q3 2025 and has held it in 3 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Larson Financial Group held 181 shares of Design Therapeutics worth $1.93K as of Q1 2026.
  • Larson Financial Group bought 178 Design Therapeutics shares in Q1 2026, an estimated $1.8K.
  • Design Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2966 holding.
  • Larson Financial Group first reported a position in Design Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.